Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

References

• Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(3):2. doi:10.1007/s11910-015-0524-6.
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Gabutti G, Stefanati A, Kuhdari P. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg. 2015;56(3):E116–20. doi:10.15167/2421-4248/jpmh2015.56.3.478.
   PubMedGoogle Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi:10.1007/s40265-013-0155-7.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Safadi MAP, Martinez AC, Marquez PI, Torres JCT, Weckx LY, Moreira Junior ED, Mensi I, Calabresi M, Toneatto D. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine. 2017;35(28):3548–3557. doi:10.1016/j.vaccine.2017.05.023.
   PubMed Web of Science ®Google Scholar
• Safadi MAP, Martinon-Torres F, Weckx LY, Moreira Junior ED, da Fonseca Lima EJ, Mensi I, Calabresi M, Toneatto D. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial. Vaccine. 2017;35(16):2052–2059. doi:10.1016/j.vaccine.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Pizza M, Masignani V, Rappuoli R. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines. 2017;16(5):433–451. doi:10.1080/14760584.2017.1308828.
   PubMed Web of Science ®Google Scholar
• Findlow J. Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned? Hum Vaccin Immunother. 2016;12(1):235–238. doi:10.1080/21645515.2015.1091131.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782. doi:10.1016/s0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45): 19490–19495.doi:10.1073/pnas.1013758107.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636. doi:10.1016/j.vaccine.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43): 4968–4974.doi:10.1016/j.vaccine.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Budroni S, Kleinschmidt A, Boucher P, Medini D. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine. 2016;34(23):2579–2584. doi:10.1016/j.vaccine.2016.04.009.
   PubMed Web of Science ®Google Scholar
• European Medicinces Agency. Assessment report Bexsero; 2012 Nov 15 accessed 2018 Jan 16. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002333/WC500137883.pdf.
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. Lancet Infect Dis. 2017;17(7): 754–762.doi:10.1016/s1473-3099(17)30170-6.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375(16):1594–1595. doi:10.1056/NEJMc1610666.
   PubMedGoogle Scholar
• Potts CC, Joseph SJ, Chang HY, Chen A, Vuong J, Hu F, Jenkins LT, Schmink S, Blain A, MacNeil JR, et al. Population structure of invasive Neisseria meningitidis in the United States, 2011-15. J J Infect. 2018;77(5):427–434. doi:10.1016/j.jinf.2018.06.008.
   Google Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413. doi:10.2307/2331986.
   Google Scholar